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Abstract
Lambda phages have considerable potential as gene delivery vehicles due to their genetic tractability, low cost, safety 
and physical characteristics in comparison to other nanocarriers and gene porters. Little is known concerning lambda 
phage-mediated gene transfer and expression in mammalian hosts. We therefore performed experiments to evaluate 
lambda-ZAP bacteriophage-mediated gene transfer and expression in vitro. For this purpose, we constructed 
recombinant λ-phage nanobioparticles containing a mammalian expression cassette encoding enhanced green 
fluorescent protein (EGFP) and E7 gene of human papillomavirus type 16 (λ-HPV-16 E7) using Lambda ZAP- CMV XR 
vector. Four cell lines (COS-7, CHO, TC-1 and HEK-239) were transduced with the nanobioparticles. We also 
characterized the therapeutic anti-tumor effects of the recombinant λ-HPV-16 E7 phage in C57BL/6 tumor mice model 
as a cancer vaccine. Obtained results showed that delivery and expression of these genes in fibroblastic cells (COS-7 
and CHO) are more efficient than epithelial cells (TC-1 and HEK-239) using these nanobioparticles. Despite the same 
phage M.O.I entry, the internalizing titers of COS-7 and CHO cells were more than TC-1 and HEK-293 cells, respectively. 
Mice vaccinated with λ-HPV-16 E7 are able to generate potent therapeutic antitumor effects against challenge with E7- 
expressing tumor cell line, TC-1 compared to group treated with the wild phage. The results demonstrated that the 
recombinant λ-phages, due to their capabilities in transducing mammalian cells, can also be considered in design and 
construction of novel and safe phage-based nanomedicines.
Introduction
Different strategies have been employed for gene delivery
and expression in mammalian cells. Two main types of
these strategies are viral and non-viral vectors [1,2]. The
most known viral vehicles having been effectively
employed as gene transfer vectors in vitro include the
vaccinia viruses [3], herpes simplex viruses[4], adenovi-
ruses[5], influenza viruses [6], lentiviruses [7] retrovi-
ruses [8], and adeno-associated viruses. Non-viral
vehicles include polymers (condensing and non-condens-
ing ones)[9], bacterial spores[10], proteosomes [11], exo-
somes [12], liposomes [13], virosomes [14], superfluids
[15], nanoparticle-based nanobeads [16], virus-liked par-
ticles [17] and bacteriophages [18].
The application of bacteriophages for gene delivery and
vaccination has already been described [19,20]. Particu-
larly, lambda bacteriophages having various appealing
characteristics as gene/vaccine delivery vehicles, possess
a high degree of stability [21], high production capacity
[22], compatibility with rapid and inexpensive production
or purification methods [23], genetic tractability and
inherent biological safety in mammalian cells [24].
The dimensions of the lambda phage particles are
broadly similar to those of many mammalian viruses and
recent structural evidence points to a shared ancestry
between tailed bacteriophages and mammalian DNA
viruses [25]. However, the eukaryotic cell poses numer-
ous barriers to phage-mediated gene transfer[25]. After
macropinocytosis and internalization, phage must gain
access to the cytoplasm, uncoat and deliver its DNA pay-
load to the nuclei.
Since little is known concerning phage-mediated gene
transfer in mammalian cells [26], we therefore performed
experiments to examine phage-mediated gene transfer in
vitro. For this purpose, recombinant lambda phages were
characterized to compare their performance for gene* Correspondence: soleim_h@modares.ac.ir1 Department of Virology, Faculty of Medical Sciences, Tarbiat Modares 
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sources.
The discovery that human papillomavirus (HPV)
causes the vast majority of cervical cancers opens exciting
new possibilities for controlling this disease, which is the
second most common cancer among women worldwide.
Vaccines that protect against HPV infection, if adminis-
tered prior to initiation of sexual activity, theoretically
would prevent women from developing cervical cancer
later in life.
Since human papillomavirus (HPV) causes the vast
majority of cervical cancers, exciting new approaches for
controlling the disease were performed. Therapeutic vac-
cines are aimed at promoting regression of HPV-associ-
ated lesions by the induction of cellular immune
responses directed against viral proteins expressed in
tumor cells[25].
Human HPV-16 E7 was also chosen for vaccine devel-
opment because HPVs, particularly HPV-16, are associ-
ated with most cervical cancers. The HPV oncogenic
proteins, E6 and E7, are important in the induction and
maintenance of cellular transformation and coexpressed
in most HPV-containing cervical cancers. Vaccines or
immunological therapeutics targeting E7 and/or E6 pro-
teins may provide an opportunity to treat HPV-associ-
ated cervical malignancy [25]. In the present study, we
have accordingly taken advantage of the bacteriophage
Lambda as a gene delivery vector for HPV-16 E7 and
evaluate anti-tumor effects of the phage in C57BL/6 mice.
The results potentially confirmed the capability of these
biological tools in offering new therapeutic strategies
against TC-1 tumors in mice.
Materials and methods
Lambda vector
Lambda ZAP®-CMV vector (Stratagene, USA) was used
for construction of recombinant λ bacteriophages. The
vector has potential characteristics for expression in
eukaryotic cells. Eukaryotic expression of inserts is driven
by the cytomegalovirus (CMV) immediate early (IE) pro-
moter with the SV40 transcription terminator and poly-
adenylation signal (Figure 1).
Bacterial strains
The RecA- E. coli host strain XL1-Blue MRF' and VCS257
strain Δ(mcrA)183 Δ(mcrCB-hsdSMR-mrr)173 endA1
thi-1 recA1 gyrA96 relA1 lac [F'proAB lacIqZΔM15 Tn10
(Tetr)] Su-(nonsuppressing) λr is supplied with the
Lambda ZAP-CMV XR predigested vector kit and
Lambda ZAP-CMV XR Gigapack® cloning kit for λ phage
amplification and titration purposes. The E. coli DH5α
were used as host cells during the cloning experiments
and for propagation of the plasmids. Bacterial strains
were routinely grown at 37°c in LB broth (Gibco BRL) or
on agar containing medium, supplemented with 50 μg/ml
ampicilin, whenever required.
Preparation of plasmid DNA
The E7 gene with flanking EcoRI and Xho I sites, respec-
tively, was synthesized by ShineGene (Shanghai Shine-
Gene Molecular Biotech, Inc) and cloned into pUC18
vector.
E. coli bacterial strain DH5α was transformed with
plasmid DNA encoding EGFP (pEGFP-C1) (BD Biosci-
ences Clontech, GenBank Accession # U55763) (Figure
1C) and pUC18 incubated in selective Luria-Bertani (LB)
medium and extracted from the culture pellets using a
QIAGEN endotoxin free Mega Plasmid kit (QIAGEN,
Hilden, Germany) according to the manufacturer's
instructions. The purity and identity of the plasmid was
confirmed by agarose gel electrophoresis.
Construction of λZAP-CMV vectors
EGFP-Lambda ZAP-CMV DNA was constructed by sub-
clonning of the EGFP fragment from pEGFP-C1 (employ-
ing primers eGFP-up: 5'-
GTAGAATTC(EcoRI)ATGGTGAGCAAGGGCGAGG-
3' and eGFP-down: 5'-GACCTCGAG(XhoI)TTACTTG-
TACAGCTCGTCC-3') into the corresponding sites in
lambda ZAP-CMV DNA [26]. For constructing λ-Zap
HPV-16 E7, The HPV-16 E7 gene was excised from the
pUC18 vector using suitable restriction enzymes to be
ligated into lambda ZAP-CMV DNA. For ligation, we
used an equal molar ratio (or less to prevent multiple
inserts) of the inserts according to the kit instruction.
The pBR322 (as a positive control of ligation) HPV-16 E7
and EGFP inserts were ligated into Lambda ZAP-CMV
vector at a volume up to 2.5 μl using 2 U of T4 DNA
ligase (Fermentaz) and 0.5 μl of 10 mM ATP (pH 7.5). For
packaging of lambda pages, the ligated DNA immediately
was added to the packaging extract. Also, 1 μl of the con-
trol ligation was added to a separate tube of packaging
extract. Then, the tube was stirred with a pipette tip to
mix well. The tube was spined quickly for 3-5 seconds.
The tube was incubated at room temperature (22°C) for 2
Figure 1 A) Presence of EGFP gene (700 bp) in packaged phages 
was confirmed using PCR. Lane 1 is negative control. Lane 2 is the re-
sult of PCR. Lane 3 is gene ruler from Fermentaz. B) Plaque formation 
by recombinant λ phages on top agar.
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buffer included 5.8 g NaCl, 2.0 g MgSO4·7H2O, 50.0 ml 1
M Tris-HCl (pH 7.5), 5.0 ml 2% (w/v) gelatin up to one
liter distilled water) was added to the tube. Then, 20 μl of
chloroform was added and mixed the contents of the
tube, gently. The tube was spined briefly to sediment the
debris. The supernatant containing the phage was ready
for titteration. The supernatant can be stored at 4°C for
up to 1 month.
DNA-packaging efficiency by Gigapack
For measurement of the interactions between DNA and
Gigapack, ethidium bromide (EtBr), a DNA-intercalating
dye, was used to examine the association of DNA with
the packaging extract [27,28]. A solution of 400 ng/ml
EtBr in HBG (20 mM HEPES, 5% (V/V) glucose, pH 7.4)
was prepared with further addition of 10 μg/ml of DNA-
Packaging extract. The fluorescence intensity of EtBr was
measured at an excitation wavelength 510 nm and emis-
sion wavelength 590 nm with a 10-nm slit using spectro-
fluorimeter RF-500 (Shimadzu, Japan) and fluorescence
was set to 100%. All measurements were done in tripli-
cate.
Tittering assembled-phage nanobioparticles
Cultures of XL1-Blue MRF' and VCS257 cells were pre-
pared in LB broth supplemented with 0.2% (w/v) maltose
(Merck) and 10 mM MgSO4 and then incubated at 37°C
for 4-6 hours (OD600 of 1.0) with vigorous agitation. The
bacteria were pelleted. Each cell pellet was gently resus-
pended in 25 ml sterile 10 mM MgSO4. The bacterial cells
were diluted to an OD600 of 0.5 with sterile 10 mM
MgSO4. For titration, the following components were
mixed: One microliter of a different dilution of the final
packaged reaction and 200 μl of XL1-Blue MRF' cells at
an OD600 of 0.5 were mixed. The cell concentration was
calculated, assuming 1 OD600 = 8 × 108 cells/ml.
The phage and the bacteria were incubated at 37°C for
15 minutes with intermittent shaking to allow the phage
to attach to the cells. NZY media (Sigma Ltd., UK) was
added to top agar, melted and cooled to 48°C, and plated
immediately onto dry, prewarmed NZY agar plates. The
plates were allowed to set for 10 minutes. Then the plates
were inverted and incubated at 37°C. Plaques would be
visible after 6-8 hours. The plaques counted and deter-
mined the titer in plaque-forming units per milliliter
(PFU/ml).
Phage amplification
Bacteriophage stocks were generated by picking a well
isolated plaque and placing the agar/agarose containing
the zone of lysis in SM solution. Resulting stock solution
were used to prepare liquid cultures of the bacteriophage.
For amplification, culture of XL1-Blue MRF' cells was
grown in LB broth with supplements, and then diluted
the cells to an OD600 of 0.5 in 10 mM MgSO4. XL1-Blue
MRF' cells were infected at an OD600 of 0.5 with bacterio-
phage in 50-100 μl of SM solution.
After 20 minutes absorption at 37°C, 4 ml of NZY
medium was added, prewarmed to 37°C, and incubated
the culture with vigorous agitation until lysis occurred
(usually 8-12 hours at 37°C). Then chloroform was added
to the lysates and continued incubation for 15 minutes at
37°C. The culture was centrifuged at 11000 × g for 10
minutes at 4°C. The supernatant was recovered, 50 μl of
chloroform added, and then stored the phage stock.
Purification of λ-phage nanobioparticles
Lysed cultures were cooled to room temperature. Deoxy-
ribonuclease I and Ribonuclease A (both Sigma Ltd., UK)
were added to a final concentration of 1 μg/ml and incu-
bated for 30 min at room temperature. NaCl was added to
1 M, and flasks were left to stand on ice for an hour. Cell
debris was removed by centrifugation at 11000 × g for 10
min at 4°C and the collected supernatants were pooled.
Solid Polyethylene glycol (PEG, Sigma Ltd., UK) was
added to a final concentration of 10% (w/v), dissolved
slowly at room temperature, then the flasks incubated at
4°C for at least 1 h. The precipitated bacteriophage parti-
cles were recovered by centrifugation at 11000 × g for 10
m at 4°C and the pellet re-suspended in SM buffer. An
equal volume of chloroform was added, and the culture
was centrifuged at 300 × g for 15 min at 4°C. The upper
aqueous phase was then removed and the bacteriophages
were pelleted by centrifugation at 11000 × g for 2 h at 4°C.
The bacteriophage pellet was re-suspended in 1-2 ml of
SM buffer at 4°C overnight, pelleted once more, and then
re-suspended in SM prior to storage or further manipula-
tion.
Transduction of mammalian cell lines
Four cell types were selected in transduction experi-
ments: COS-7 simian-derived kidney, CHO Chinese
hamster ovary, TC-1 C57BL/6 mouse lung epithelial cells
(Part of the Johns Hopkins Special Collection) and HEK-
293 human embryonic kidney epithelial cell lines were
cultured in RPMI 1640 (Gibco BRL, Paisley, UK) supple-
mented with 10% fetal bovine serum, and 100 U/ml peni-
cillin, 100 μg/ml streptomycin (components from Sigma,
Germany), and 2 mM L-glutamine. After overnight incu-
bation, culture medium was removed and replaced with
serum-free medium 30 min prior to the addition of λ-
phage nanobioparticles containing enhanced green fluo-
rescent protein (EGFP). Phage nanobioparticles at a mul-
tiplicity of infection (M.O.I) of 106 were added to
mammalian cell lines. Transduction of target cells was
enhanced using spinoculation or centrifugal enhance-
ment after addition of phage particles [26]. Briefly, cell
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Following centrifugation, cells were incubated for an
additional 10 min at 37°C and phage containing media
was removed and cell were washed twice with 1× PBS and
then incubated in complete media. After 36 hours post
infection, the cells were examined by fluorescent micros-
copy. Transfected COS-7 cells by wild type λ-phages were
used as negative control.
SDS-PAGE and Western blot
To confirm the expression of recombinant HPV E7 in the
cell lines, western blot analysis was performed on the
extracted total protein. CHO Cells growing on 6-cm
plates were infected with lambda ZAP-E7 particles or
wild λ-particles as a control at a multiplicity of infection
(M.O.I) of 106 and allowed to express the protein for 48 h.
Then, the cells were washed twice with ice cold phos-
phate-buffered saline (PBS) and lysed in sodium dodecyl
sulfate (SDS) loading buffer containing 1 mM dithiothre-
itol. Cellular proteins were separated on 15% polyacryl-
amide gels by SDS-polyacrylamide gel electrophoresis
(PAGE), blotted onto polyvinylidene difluoride mem-
branes (Roche, Germany), and hybridized with the
monoclonal HPV-16 E7 mouse antibody (Abcam, UK),
followed by detection with goat anti-mouse secondary
antibody conjugated to alkaline phosphatase (Sigma, St
Louis, MO) in secondary antibody solution. Color was
developed by incubating the membrane in alkaline phos-
phate buffer containing NBT (nitro blue tetrazolium) and
BCIP (bromochloroindolyl phosphatase.
In vitro internalization assay
Cells were seeded at 1 × 105 cells per well in a 96 well flat
bottom plate and 1 × 1011 plaque forming unite (PFU)
(M.O.I multiplicity of infectious 1 × 105) of EGFP-λ-
phages were added. Plates were incubated at 37°C for 4
hours. Following incubation, the cells were trepsinized
and resuspended in 1× PBS and transferred to a micro-
centrifuge tube. The cells were pelleted by centrifugation
and resuspended in an ice cold wash (0.3 M acetic acid,
0.5 M NaCl, pH 2.5) three times to remove any phage
bound to the cell exterior. After the acid wash, the cells
were washed once in 1× PBS, pelleted and resuspended in
1× TE (Tris-EDTA) and then manually lysed by passing
through a 22G insulin syringe 10 times to sheer the cells.
The lysed cells were centrifuged to remove cellular debris
and phage containing supernatant. Internalized phages in
cell lysates were then quantified by titration on E. coli
cells.
Tumor Therapy Assay
C57BL/6 mice (6-8 weeks old) were purchased from the
Pasteur Institute (Karaj, Iran). Mice were housed for 1
week before the experiment. All experiments were done
according to the guidelines for the care and use and the
guidelines of the laboratory animal ethical commission of
Tarbiat Modares University.
TC-1, was derived from primary epithelial cells of
C57BL/6 mice cotransformed with HPV16 E6 and E7 and
activated c-Ha-ras oncogene. TC-1 cell line which is
HPV-16 E7+ was used as a tumor model in an H-2b
murine system. For in vivo therapeutic experiments,
C57BL/6 mice (seven per group) were challenged by sub-
cutaneous injection in the right flank with TC-1 cells 2 ×
105 suspended in 100 μl PBS. After one week, the mice
were immunized with 2 × 1012 particles of recombinant λ-
ZAP E7 phage, wild λ-ZAP phage (phage control) and
PBS (negative control) via subcutaneous injection. Mice
received two boosts with the same regimen 1 and 2 weeks
later.
Subcutaneous tumor volume was estimated according
to Carlsson's formula. Hence, the largest (a) and the
smallest (b) superficial diameters of the tumor were mea-
sured twice a week and then the volume (V) of the tumor
was calculated (V = a × b × 1/2). To compare results
between the different groups, a one way ANOVA test was
used. The statistical software SPSS 11.0 was utilized for
statistical analyses. Differences were considered statisti-
cally significant when P value < 0.05. All values were
expressed as means ± S.D.
Results
Confirmation of EGFP and E7 lambda cassettes
Presence of EGFP and E7 genes in packaged phages was
confirmed by polymerase chain reaction using eGFP
primers and E7 primers, respectively. Also, the plaque
formation of phages on top agar approved subclonning
and ligation steps (Figure 1).
Packaging efficiency
Packaging analysis using EtBr-dye indicates an equal fluo-
rescent intensity (IF) for lambda DNAs (wild-L-DNA,
pBR322-L-DNA, E7-L-DNA and EGFP-L-DNA) before
packaging by Gigapck contained lambda protein lysates.
The DNAs showed different behaviors after EtBr interca-
lation (Figure 2). The packaging efficiencies for pBR322-
L-DNA, EGFP-L-DNA, and E7-L-DNA were respectively
measured as 91%, 64%, and 63.3% in comparison to wild-
L-DNA (100% packaging efficiency).
Gene delivery and expression
To test functionality of the EGFP expression cassette in
recombinant λ phages, four different cell lines were trans-
duced by phage particles and then examined the cells by
fluorescent microscopy after 36 h. The best GFP levels
were detected in CHO cell line (Figure 3). Thus, the
mammalian GFP expression cassette in λ phages was
functional and λ-EGFP phage transduced an EGFP gene
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from a functional expression cassette within the phage
genome suggests that the phage may not be efficiently
internalizing into the other cell lines
SDS-PAGE and Western blot
Western blot analysis was performed on lysates (106
cells), 48 hr post transfection, and it showed a signal cor-
responding to the E7 protein (11 kDa; Figure 4).
Internalization assays
The internalizing analyses on four cell lines (COS-7, TC-
1, HEK-293, and CHO) showed that the titer of internal-
ized phages is different according to the kinds of cells.
Meanwhile it was shown that wash buffer containing
Tris-EDTA didn't have any side effects on phage titer
(Data not shown). The internalizing titer was calculated 2
× 104 PFU for COS-7 cells and 5.5 × 104 PFU for CHO
cells, whereas the range was 2 × 103 and 1 × 103 for TC-1
and HEK-293 cells, respectively. It seems that these varia-
tions in internalizations maybe because of the source of
the cells (Figure 5). As a consequent, COS-7 cells with
fibroblastic source had optimum capability for phage
internalization and gene expression, whereas the two
other cells with epithelial sources had fewer capabilities
for phage entrances and gene expressions.
Therapeutic antitumor assay
To determine anti-tumor activity of recombinant λ-ZAP
E7 phage could, we performed an in vivo tumor treat-
ment experiment using a previously characterized E7-
expressing tumor model, TC-1 [19]. Tumors were mea-
sured twice a week once the tumors became palpable.
Controls consisted of unimmunized mice challenged with
tumors. The tumor volume was monitored up to 30 days
Figure 4 SDS-PAGE and Western blot analyses of CHO cells infect-
ed with E7-λ-phages. After overnight incubation, the cellular proteins 
were extracted and analyzed by SDS-PAGE and immunoblotting.
Figure 5 The internalizing analyses for four cell lines (COS-7, TC-
1, HEK-293, and CHO).
Figure 2 Packaging efficiency of wild-λ-DNA, pBR322-λ-DNA, 
EGFP-λ-DNA, and E7-λ-DNA before (series 2) and after (series 1) 
packaging using Gigapack.
Figure 3 A. CHO cells transfected by EGFP-λ-phage nanobioparti-
cles using fluorescent microscopy. Four cell types COS-7, CHO, TC-1 
and HEK-293 were transfected by EGFP-λ-phages. The best GFP ex-
pression was observed after 48 hours by fluorescent microscopy 48 
hours later in CHO cells. B. CHO experimental control.
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treated with recombinant λ-ZAP E7 phage significantly
reduced tumor volume, compared to mice treated with
the wild λ-ZAP phage and PBS (P < 0.05). These results
indicate that vaccination with recombinant λ-ZAP E7
phage could induce significant therapeutic anti-tumor
effects than vaccination with control groups.
Discussion
Many cancer vaccines currently under investigation are
based on recombinant carriers such as viruses and bacte-
ria [29]. In animal models, these vaccines can elicit pow-
erful immune responses that lead to tumor cell
destruction, but a number of obstacles remain in the
translation of these strategies to the clinic [30]. One of the
major difficulties is high pre-existing, neutralizing titers
to vaccines based on human viruses and bacteria, likely as
the result of ubiquitous exposure with this agents [31].
One way of circumventing pre-existing immunity is the
use of viruses whose natural hosts are non-mammalian
such as bacteriophages.
In the present study, the construction and characteriza-
tion of recombinant lambda bacteriophages for gene
delivery and expression in mammalian cells were
reported as a cancer-candidate vaccine. There are few
reports about using lambda phages for this purpose, but
some aspects of these biological tools have not been stud-
ied so far [32]. For example, like other nanocarriers, it is
interesting to measure the packaging efficiency of the
phage lysates when they package different sizes of the
lambda DNAs. Therefore, the packaging efficiency of λ-
phage nanobioparticles was estimated by different sizes
of DNAs. Higher packaging efficiency was obtained from
the lambda-based cassette consisting of pBR322 with a
larger DNA in comparison to the EGFP DNA. It was
demonstrated that the maximum packaging of lambda
lysates for the vector contained the wild type of lambda-
phage DNA (figure 2).
EGFP expression in CHO cells indicated the efficiency
of lambda phages as biological nanocarriers in gene deliv-
ery to mammalian cells.
Results from the internalization assays (figure 5)
showed the phage particles could be internalized more
efficiently in the fibroblastic cells (i.e., COS-7 and CHO).
However, the epithelial cells (such as TC-1 and HEK-293)
had less capability for macropinocytosis of phage nano-
bioparticles. This means, although the significant num-
bers of cells internalize the phages, the cells do not
essentially express the EGFP gene. The fact suggests the
transduction frequency of phages is limited by one or
more post-uptake events [21,33].
In vivo experiment demonstrated efficient therapeutic
anti-tumor effects of recombinant lambda phage contain-
ing HPV-16 E7. The antitumor cell-mediated immune
responses induced by recombinant phages are likely to
play a role in this function. It seems that Natural immu-
nostimulatory of the lambda phage enhance the anti-
tumor effects of recombinant phage.
March et al described lambda-gt11 (having CMV pro-
moter) vector as gene delivery system and vaccine [21],
the lambda-based vector presented here for the first time
uses lambda ZAP CMV vector. Further researches aimed
at improving their efficiency, lysosomal escape, transgene
nuclear localization, or transgene cassette stability during
cell division will contribute to the production of more
effective tools for gene transfer experiments, eventually
providing efficient eukaryotic viral vectors. Our work has
increased the understanding of lambda-phage-mediated
gene transfer and suggests new approaches may lead to
the design of potential phage nanomedicines for novel
phage-based drugs and vaccines in future[21-23].
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Figure 6 Therapeutic vaccination against TC-1-induced tumors. 
Mice were inoculated with 2 × 105 TC-1 tumor into the right flank and 
then treated with recombinant λ-ZAP E7 phage, Wild λ-ZAP phage 
(phage control) and PBS (negative control) 7 days after inoculation. 
Mice were monitored for evidence of tumor growth by palpation and 
inspection twice a week. For determining of tumor volume, each indi-
vidual tumor size was measured. Line and scatter plot graphs depict-
ing the tumor volume (mm3) are presented. The data presented is a 
representation of two independent experiments.
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